NAMENDA
LOE ApproachingNDAORALSOLUTION
Approved
Apr 2005
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
4/8 — Partial
NAMENDA by AbbVie is n-methyl-d-aspartate (nmda) receptors by the excitatory amino acid glutamate has been hypothesized to contribute to the symptomatology of alzheimer's disease. Approved for moderate to severe dementia of the alzheimer's type, moderate to severe dementia of the alzheimer's type (). First approved in 2005.
Drug data last refreshed 14h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NAMENDA (memantine) is an oral small-molecule NMDA receptor antagonist approved for moderate to severe Alzheimer's disease dementia. It works by blocking glutamate-mediated excitotoxicity at NMDA receptor-operated cation channels, though it does not prevent or slow neurodegeneration. The drug is available as an oral solution formulation.
$0.063BPart D
LOE ApproachingProduct is approaching loss of exclusivity with modest Medicare spending of $63K and only 142 claims in 2023, signaling a small, stable brand team focused on maintenance.
Mechanism of Action
N-methyl-D-aspartate (NMDA) receptors by the excitatory amino acid glutamate has been hypothesized to contribute to the symptomatology of Alzheimer's disease. Memantine is postulated to exert its therapeutic effect through its action as a low to moderate affinity uncompetitive (open-channel) NMDA…
Worked on NAMENDA at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.